AVANIR Pharmaceuticals Holds Annual Meeting of Shareholders
06 Febbraio 2006 - 6:15PM
Business Wire
AVANIR Pharmaceuticals (AMEX:AVN.R) reported on the results of its
2006 Annual Meeting of Shareholders held today. Eric K. Brandt,
AVANIR's President and Chief Executive Officer, Charles A. Mathews,
Chairman of the Board at AVANIR Pharmaceuticals, and Jonathan T.
Silverstein, General Partner at OrbiMed Advisors LLC, were all
re-elected to the Board as Class II Directors to serve a three-year
term. In addition to the three Directors elected at this meeting,
the Directors continuing in office are Stephen G. Austin, David J.
Mazzo, Ph.D., Dennis G. Podlesak, Paul G. Thomas, Craig A. Wheeler
and Scott M. Whitcup, Ph.D. All of the directors, with the
exception of Eric Brandt, are independent outside directors. In
addition to electing the Directors, the shareholders also approved
an amendment to the Company's 2005 Equity Incentive Plan and
ratified the selection of Deloitte & Touche, LLP as the
Company's independent registered public accounting firm for the
fiscal year ending September 30, 2006. A proposal to renew the
Board of Directors' authorization to implement a reverse stock
split was withdrawn, because a one-for-four reverse split was
enacted in January 2006. ABOUT AVANIR AVANIR Pharmaceuticals is
focused on developing and commercializing novel therapeutic
products for the treatment of chronic diseases. AVANIR's product
candidates address therapeutic markets that include central nervous
system and cardiovascular disorders, inflammation, and infectious
disease. AVANIR previously announced positive results in the second
of two required Phase III clinical trials of Neurodex(TM), an
investigational new drug for the treatment of involuntary emotional
expression disorder (IEED). Additionally, AVANIR has initiated a
Phase III clinical trial for Neurodex as a potential treatment in
patients with diabetic neuropathic pain, a second indication for
Neurodex. AVANIR has active collaborations with two international
pharmaceutical companies: Novartis International Pharmaceutical
Ltd. for the treatment of inflammatory disease and AstraZeneca for
the treatment of cardiovascular disease. The Company's first
commercialized product, abreva(R), is marketed in North America by
GlaxoSmithKline Consumer Healthcare and is the leading
over-the-counter product for the treatment of cold sores. Further
information about AVANIR can be found at www.avanir.com. FORWARD
LOOKING STATEMENT The information contained in this press release,
including any forward-looking statements contained herein, should
be reviewed in conjunction with the Company's most recent Annual
Report on Form 10-K and quarterly report on Form 10-Q and other
publicly available information regarding the Company. Copies of
such information are available from the company upon request. Such
publicly available information sets forth many risks and
uncertainties related to the company's business and technology.
Forward-looking statements often contain such words like
"estimate," "anticipate," "believe," "plan" or "expect." AVANIR
disclaims any intent or obligation to update these forward-looking
statements.
Grafico Azioni Avanir (AMEX:AVN.R)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Avanir (AMEX:AVN.R)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Avanir Pharmaceuticl (Borsa Americana (AMEX)): 0 articoli recenti
Più AVANIR Pharmaceuticals Articoli Notizie